[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fQjV78-uRshsUuCZ73lpDYM9VEr7gA9DaYxxM3liT-9o":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":32,"phaseBuckets":48,"rows":55},"University Hospital, Linkoeping",[4],118,false,13,5,947709,4,92,[14,16,18,21,23,25,27,30],{"name":15,"count":9},"Frailty",{"name":17,"count":11},"Osteoporosis",{"name":19,"count":20},"Healthy Subjects",3,{"name":22,"count":20},"Burns",{"name":24,"count":20},"Cardiovascular Disease",{"name":26,"count":20},"Rotator Cuff Tear",{"name":28,"count":29},"Trauma",2,{"name":31,"count":29},"Myocardial Infarction",[33,38,43],{"nctId":34,"briefTitle":35,"date":36,"intervention":37},"NCT06270017","Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars","2025-12-31","Chemotherapy drug",{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT05284552","Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer","2027-12","Tinzaparin Injectable Solution",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT05169229","Antibiotic Impregnated Bone Graft to Reduce Infection in Hip Replacement.","2028-12","Vancomycin + Tobramycin",[49,50,51,52,53,54],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[56,100,118,155,175,222,246,270,295,323,347,365,391,420,438,456,474,508,530,556,582,610,628,646,671,696,728,746,764,782,800,818,844,862,889,907],{"intervention":57,"totalTrials":29,"cells":58},"saline",{"EARLY_PHASE1":59,"PHASE1":62,"PHASE2":64,"PHASE3":66,"PHASE4":96,"NA":98},{"trials":60,"activeCount":61},[],0,{"trials":63,"activeCount":61},[],{"trials":65,"activeCount":61},[],{"trials":67,"activeCount":95,"soonestReadout":46},[68,82],{"nctId":69,"briefTitle":70,"status":71,"phases":72,"primaryCompletion":73,"completion":73,"start":74,"enrollment":75,"conditions":76,"interventions":80},"NCT02592824","Glutamate for Metabolic Intervention in Coronary Surgery II","COMPLETED",[52],"2020-10-30","2015-11-15",321,[77,78,79],"Coronary Artery Bypass Surgery","Postoperative Complications","Heart Failure",[81,57],"glutamate",{"nctId":44,"briefTitle":45,"status":83,"phases":84,"primaryCompletion":46,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":93},"RECRUITING",[51,52],"2031-12","2022-04-01",1100,[89,90,91,92],"Arthroplasty, Replacement, Hip","Osteoarthritis, Hip","Antibiotic Resistant Infection","Prosthetic Joint Infection",[47,94],"Saline",1,{"trials":97,"activeCount":61},[],{"trials":99,"activeCount":61},[],{"intervention":47,"totalTrials":95,"cells":101},{"EARLY_PHASE1":102,"PHASE1":104,"PHASE2":106,"PHASE3":108,"PHASE4":114,"NA":116},{"trials":103,"activeCount":61},[],{"trials":105,"activeCount":61},[],{"trials":107,"activeCount":61},[],{"trials":109,"activeCount":95,"soonestReadout":46},[110],{"nctId":44,"briefTitle":45,"status":83,"phases":111,"primaryCompletion":46,"completion":85,"start":86,"enrollment":87,"conditions":112,"interventions":113},[51,52],[89,90,91,92],[47,94],{"trials":115,"activeCount":61},[],{"trials":117,"activeCount":61},[],{"intervention":37,"totalTrials":29,"cells":119},{"EARLY_PHASE1":120,"PHASE1":122,"PHASE2":124,"PHASE3":149,"PHASE4":151,"NA":153},{"trials":121,"activeCount":61},[],{"trials":123,"activeCount":61},[],{"trials":125,"activeCount":95,"soonestReadout":36},[126,134],{"nctId":34,"briefTitle":35,"status":83,"phases":127,"primaryCompletion":36,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":133},[50,51],"2028-12-31","2022-01-10",300,[132],"Colon Cancer",[37],{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":140,"start":141,"enrollment":142,"conditions":143,"interventions":148},"NCT05289076","Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model","UNKNOWN",[50,51],"2024-03-14","2025-03-14","2022-05-17",40,[144,145,146,147],"Colorectal Cancer Metastatic","Tumour Metastasis","Chemotherapy Effect","Tumor Growth",[37],{"trials":150,"activeCount":61},[],{"trials":152,"activeCount":61},[],{"trials":154,"activeCount":61},[],{"intervention":42,"totalTrials":95,"cells":156},{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":169,"PHASE4":171,"NA":173},{"trials":158,"activeCount":61},[],{"trials":160,"activeCount":61},[],{"trials":162,"activeCount":95,"soonestReadout":41},[163],{"nctId":39,"briefTitle":40,"status":83,"phases":164,"primaryCompletion":41,"completion":41,"start":165,"enrollment":142,"conditions":166,"interventions":168},[51],"2022-07-12",[167],"Epithelial Ovarian Cancer",[42],{"trials":170,"activeCount":61},[],{"trials":172,"activeCount":61},[],{"trials":174,"activeCount":61},[],{"intervention":176,"totalTrials":20,"cells":177},"Teriparatide",{"EARLY_PHASE1":178,"PHASE1":180,"PHASE2":182,"PHASE3":195,"PHASE4":197,"NA":220},{"trials":179,"activeCount":61},[],{"trials":181,"activeCount":61},[],{"trials":183,"activeCount":61},[184],{"nctId":185,"briefTitle":186,"status":71,"phases":187,"primaryCompletion":188,"completion":188,"start":189,"enrollment":190,"conditions":191,"interventions":193},"NCT01063504","Teriparatide for Improved Knee Prosthesis Fixation",[51],"2013-06","2010-02",60,[192],"Osteoarthritis of the Knee",[194],"teriparatide",{"trials":196,"activeCount":61},[],{"trials":198,"activeCount":61},[199,209],{"nctId":200,"briefTitle":201,"status":71,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":142,"conditions":206,"interventions":208},"NCT01105832","Does Teriparatide (rhPTH 1-34) Promote Fracture Healing in Proximal Humeral Fractures?",[53],"2014-02","2014-09","2010-04",[207],"Humeral Fracture",[176],{"nctId":210,"briefTitle":211,"status":71,"phases":212,"primaryCompletion":213,"completion":214,"start":215,"enrollment":216,"conditions":217,"interventions":219},"NCT02090244","Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?",[53],"2018-05","2019-01-01","2012-08",34,[218],"Spinal Stenosis",[176],{"trials":221,"activeCount":61},[],{"intervention":223,"totalTrials":95,"cells":224},"Albumins",{"EARLY_PHASE1":225,"PHASE1":227,"PHASE2":229,"PHASE3":231,"PHASE4":233,"NA":244},{"trials":226,"activeCount":61},[],{"trials":228,"activeCount":61},[],{"trials":230,"activeCount":61},[],{"trials":232,"activeCount":61},[],{"trials":234,"activeCount":61},[235],{"nctId":236,"briefTitle":237,"status":71,"phases":238,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT02952378","Volume Kinetics for Hyperoncotic Albumin in Burn Patients as Well as for Healthy Subjects",[53],"2019-01-31","2016-10",30,[22],[223],{"trials":245,"activeCount":61},[],{"intervention":247,"totalTrials":95,"cells":248},"Albumin solution",{"EARLY_PHASE1":249,"PHASE1":251,"PHASE2":253,"PHASE3":255,"PHASE4":257,"NA":268},{"trials":250,"activeCount":61},[],{"trials":252,"activeCount":61},[],{"trials":254,"activeCount":61},[],{"trials":256,"activeCount":61},[],{"trials":258,"activeCount":61},[259],{"nctId":260,"briefTitle":261,"status":71,"phases":262,"primaryCompletion":239,"completion":239,"start":263,"enrollment":264,"conditions":265,"interventions":267},"NCT03453320","Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects",[53],"2018-02-24",12,[266],"Edema Secondary",[247],{"trials":269,"activeCount":61},[],{"intervention":271,"totalTrials":95,"cells":272},"Ziconotide",{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":281,"NA":293},{"trials":274,"activeCount":61},[],{"trials":276,"activeCount":61},[],{"trials":278,"activeCount":61},[],{"trials":280,"activeCount":61},[],{"trials":282,"activeCount":61},[283],{"nctId":284,"briefTitle":285,"status":71,"phases":286,"primaryCompletion":287,"completion":287,"start":288,"enrollment":289,"conditions":290,"interventions":292},"NCT01373983","Intrathecal Bolus Doses of Ziconotide",[53],"2014-12","2011-08",26,[291],"Peripheral Neuropathy",[271],{"trials":294,"activeCount":61},[],{"intervention":296,"totalTrials":95,"cells":297},"Intravenous infusion of saline",{"EARLY_PHASE1":298,"PHASE1":300,"PHASE2":302,"PHASE3":304,"PHASE4":319,"NA":321},{"trials":299,"activeCount":61},[],{"trials":301,"activeCount":61},[],{"trials":303,"activeCount":61},[],{"trials":305,"activeCount":61},[306],{"nctId":307,"briefTitle":308,"status":71,"phases":309,"primaryCompletion":310,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":318},"NCT00489827","Glutamate for Metabolic Intervention in Coronary Surgery",[52],"2009-12","2022-08","2005-10",865,[315,316,31,317],"Coronary Artery Bypass","Myocardial Ischemia","Coronary Artery Disease",[296],{"trials":320,"activeCount":61},[],{"trials":322,"activeCount":61},[],{"intervention":324,"totalTrials":95,"cells":325},"17-beta-estradiol",{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":343,"NA":345},{"trials":327,"activeCount":61},[],{"trials":329,"activeCount":61},[],{"trials":331,"activeCount":61},[],{"trials":333,"activeCount":61},[334],{"nctId":335,"briefTitle":336,"status":137,"phases":337,"completion":338,"start":339,"conditions":340,"interventions":342},"NCT00204074","Treatment of Menstrual Migraine With Sequential, Transdermal, 17-Beta-Estradiol. A Double-Blind, Randomised, Cross-Over Trial.",[51,52],"2005-07","2001-10",[341],"Migraine",[324],{"trials":344,"activeCount":61},[],{"trials":346,"activeCount":61},[],{"intervention":81,"totalTrials":95,"cells":348},{"EARLY_PHASE1":349,"PHASE1":351,"PHASE2":353,"PHASE3":355,"PHASE4":361,"NA":363},{"trials":350,"activeCount":61},[],{"trials":352,"activeCount":61},[],{"trials":354,"activeCount":61},[],{"trials":356,"activeCount":61},[357],{"nctId":69,"briefTitle":70,"status":71,"phases":358,"primaryCompletion":73,"completion":73,"start":74,"enrollment":75,"conditions":359,"interventions":360},[52],[77,78,79],[81,57],{"trials":362,"activeCount":61},[],{"trials":364,"activeCount":61},[],{"intervention":366,"totalTrials":95,"cells":367},"Celecoxib",{"EARLY_PHASE1":368,"PHASE1":370,"PHASE2":372,"PHASE3":374,"PHASE4":387,"NA":389},{"trials":369,"activeCount":61},[],{"trials":371,"activeCount":61},[],{"trials":373,"activeCount":61},[],{"trials":375,"activeCount":61},[376],{"nctId":377,"briefTitle":378,"status":137,"phases":379,"primaryCompletion":380,"completion":381,"start":382,"enrollment":383,"conditions":384,"interventions":386},"NCT00300729","Effect of Celecoxib on Survival in Patients With Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy",[52],"2010-05","2010-09","2006-05",319,[385],"Non-Small Cell Lung Cancer",[366],{"trials":388,"activeCount":61},[],{"trials":390,"activeCount":61},[],{"intervention":392,"totalTrials":95,"cells":393},"rifampicin",{"EARLY_PHASE1":394,"PHASE1":396,"PHASE2":398,"PHASE3":414,"PHASE4":416,"NA":418},{"trials":395,"activeCount":61},[],{"trials":397,"activeCount":61},[],{"trials":399,"activeCount":61},[400],{"nctId":401,"briefTitle":402,"status":403,"phases":404,"primaryCompletion":405,"completion":406,"start":407,"enrollment":142,"conditions":408,"interventions":410},"NCT04694586","Drug Exposure and Safety of a Shorter Tuberculosis Treatment Based on High-Dose Rifampicin and Pyrazinamide","SUSPENDED",[51],"2024-05-31","2026-05-31","2022-11-30",[409],"Tuberculosis, Pulmonary",[392,411,412,413],"pyrazinamide","HRZE","HR",{"trials":415,"activeCount":61},[],{"trials":417,"activeCount":61},[],{"trials":419,"activeCount":61},[],{"intervention":411,"totalTrials":95,"cells":421},{"EARLY_PHASE1":422,"PHASE1":424,"PHASE2":426,"PHASE3":432,"PHASE4":434,"NA":436},{"trials":423,"activeCount":61},[],{"trials":425,"activeCount":61},[],{"trials":427,"activeCount":61},[428],{"nctId":401,"briefTitle":402,"status":403,"phases":429,"primaryCompletion":405,"completion":406,"start":407,"enrollment":142,"conditions":430,"interventions":431},[51],[409],[392,411,412,413],{"trials":433,"activeCount":61},[],{"trials":435,"activeCount":61},[],{"trials":437,"activeCount":61},[],{"intervention":412,"totalTrials":95,"cells":439},{"EARLY_PHASE1":440,"PHASE1":442,"PHASE2":444,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":441,"activeCount":61},[],{"trials":443,"activeCount":61},[],{"trials":445,"activeCount":61},[446],{"nctId":401,"briefTitle":402,"status":403,"phases":447,"primaryCompletion":405,"completion":406,"start":407,"enrollment":142,"conditions":448,"interventions":449},[51],[409],[392,411,412,413],{"trials":451,"activeCount":61},[],{"trials":453,"activeCount":61},[],{"trials":455,"activeCount":61},[],{"intervention":413,"totalTrials":95,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":468,"PHASE4":470,"NA":472},{"trials":459,"activeCount":61},[],{"trials":461,"activeCount":61},[],{"trials":463,"activeCount":61},[464],{"nctId":401,"briefTitle":402,"status":403,"phases":465,"primaryCompletion":405,"completion":406,"start":407,"enrollment":142,"conditions":466,"interventions":467},[51],[409],[392,411,412,413],{"trials":469,"activeCount":61},[],{"trials":471,"activeCount":61},[],{"trials":473,"activeCount":61},[],{"intervention":475,"totalTrials":29,"cells":476},"Loperamide",{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":485,"NA":487},{"trials":478,"activeCount":61},[],{"trials":480,"activeCount":61},[],{"trials":482,"activeCount":61},[],{"trials":484,"activeCount":61},[],{"trials":486,"activeCount":61},[],{"trials":488,"activeCount":61},[489,500],{"nctId":490,"briefTitle":491,"status":137,"phases":492,"primaryCompletion":493,"completion":494,"start":495,"conditions":496,"interventions":498},"NCT02888899","Tibial Nerve Stimulation in Combination With Biofeedback",[54],"2018-03","2019-03","2016-03",[497],"Fecal Incontinence",[475,499],"Stool bulking agent",{"nctId":501,"briefTitle":502,"status":71,"phases":503,"primaryCompletion":504,"start":505,"conditions":506,"interventions":507},"NCT02165475","Combination Therapy With Biofeedback, Loperamide and Stool Bulking Agents",[54],"2005-03","2002-05",[497],[475,499],{"intervention":499,"totalTrials":29,"cells":509},{"EARLY_PHASE1":510,"PHASE1":512,"PHASE2":514,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":511,"activeCount":61},[],{"trials":513,"activeCount":61},[],{"trials":515,"activeCount":61},[],{"trials":517,"activeCount":61},[],{"trials":519,"activeCount":61},[],{"trials":521,"activeCount":61},[522,526],{"nctId":490,"briefTitle":491,"status":137,"phases":523,"primaryCompletion":493,"completion":494,"start":495,"conditions":524,"interventions":525},[54],[497],[475,499],{"nctId":501,"briefTitle":502,"status":71,"phases":527,"primaryCompletion":504,"start":505,"conditions":528,"interventions":529},[54],[497],[475,499],{"intervention":531,"totalTrials":95,"cells":532},"SodiumChloride",{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":539,"PHASE4":541,"NA":543},{"trials":534,"activeCount":61},[],{"trials":536,"activeCount":61},[],{"trials":538,"activeCount":61},[],{"trials":540,"activeCount":61},[],{"trials":542,"activeCount":61},[],{"trials":544,"activeCount":61},[545],{"nctId":546,"briefTitle":547,"status":71,"phases":548,"primaryCompletion":549,"completion":550,"start":551,"enrollment":552,"conditions":553,"interventions":555},"NCT02172092","Fluid Kinetics in Patients With Diabetic Ketoacidosis",[54],"2018-12","2019-02","2014-08",17,[554],"Diabetes",[531],{"intervention":557,"totalTrials":95,"cells":558},"endotoxin escherichia coli",{"EARLY_PHASE1":559,"PHASE1":561,"PHASE2":563,"PHASE3":565,"PHASE4":567,"NA":569},{"trials":560,"activeCount":61},[],{"trials":562,"activeCount":61},[],{"trials":564,"activeCount":61},[],{"trials":566,"activeCount":61},[],{"trials":568,"activeCount":61},[],{"trials":570,"activeCount":61},[571],{"nctId":572,"briefTitle":573,"status":71,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":581},"NCT06618716","Individual Differences in Acute Response to Experimental Inflammation: Microcirculatory Changes and Psychological Predictors",[54],"2025-03-11","2024-09-17",25,[579,580],"Inflammation Biomarkers","Inflammation",[557],{"intervention":583,"totalTrials":95,"cells":584},"acetated Ringers",{"EARLY_PHASE1":585,"PHASE1":587,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":586,"activeCount":61},[],{"trials":588,"activeCount":61},[],{"trials":590,"activeCount":61},[],{"trials":592,"activeCount":61},[],{"trials":594,"activeCount":61},[],{"trials":596,"activeCount":61},[597],{"nctId":598,"briefTitle":599,"status":71,"phases":600,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":604,"interventions":607},"NCT01195025","Volume Kinetics for Starch Solution and Acetated Ringers",[54],"2011-05","2010-08",10,[605,606],"Blood Volume","Blood Coagulation",[583,608,609],"colloid","colloid+acetated Ringer",{"intervention":608,"totalTrials":95,"cells":611},{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":613,"activeCount":61},[],{"trials":615,"activeCount":61},[],{"trials":617,"activeCount":61},[],{"trials":619,"activeCount":61},[],{"trials":621,"activeCount":61},[],{"trials":623,"activeCount":61},[624],{"nctId":598,"briefTitle":599,"status":71,"phases":625,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":626,"interventions":627},[54],[605,606],[583,608,609],{"intervention":609,"totalTrials":95,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":631,"activeCount":61},[],{"trials":633,"activeCount":61},[],{"trials":635,"activeCount":61},[],{"trials":637,"activeCount":61},[],{"trials":639,"activeCount":61},[],{"trials":641,"activeCount":61},[642],{"nctId":598,"briefTitle":599,"status":71,"phases":643,"primaryCompletion":601,"completion":601,"start":602,"enrollment":603,"conditions":644,"interventions":645},[54],[605,606],[583,608,609],{"intervention":647,"totalTrials":95,"cells":648},"Sodium chloride",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":650,"activeCount":61},[],{"trials":652,"activeCount":61},[],{"trials":654,"activeCount":61},[],{"trials":656,"activeCount":61},[],{"trials":658,"activeCount":61},[],{"trials":660,"activeCount":61},[661],{"nctId":662,"briefTitle":663,"status":664,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":95,"conditions":668,"interventions":670},"NCT03703713","Colloid Osmotic Pressure and Osmolality in Hyponatremia","TERMINATED",[],"2020-12-31","2018-10-09",[669],"Hyponatremia",[647],{"intervention":672,"totalTrials":95,"cells":673},"Ropivacaine",{"EARLY_PHASE1":674,"PHASE1":676,"PHASE2":678,"PHASE3":680,"PHASE4":682,"NA":684},{"trials":675,"activeCount":61},[],{"trials":677,"activeCount":61},[],{"trials":679,"activeCount":61},[],{"trials":681,"activeCount":61},[],{"trials":683,"activeCount":61},[],{"trials":685,"activeCount":61},[686],{"nctId":687,"briefTitle":688,"status":137,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":695},"NCT05365555","Blind Fascia Iliaca Compartment Block Compared to Ultrasound-guided Femoral Nerve Block in Patients With Hip Fractures",[],"2023-04","2022-05-01",100,[694],"Hip Fractures",[672],{"intervention":697,"totalTrials":95,"cells":698},"Acetylcholine",{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":705,"PHASE4":707,"NA":709},{"trials":700,"activeCount":61},[],{"trials":702,"activeCount":61},[],{"trials":704,"activeCount":61},[],{"trials":706,"activeCount":61},[],{"trials":708,"activeCount":61},[],{"trials":710,"activeCount":61},[711],{"nctId":712,"briefTitle":713,"status":664,"phases":714,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":719,"interventions":722},"NCT04777383","The Effects of Iontophoresed Vasoactive Drugs on Cutaneus Blood Flow",[54],"2021-10-15","2021-10-31","2019-04-01",31,[720,721],"Cardiovascular Diseases","Vascular Diseases",[697,723,724,725,726,727],"Norepinephrine","Phenylephrine","Atropine","Neostigmine","Sterile water",{"intervention":723,"totalTrials":95,"cells":729},{"EARLY_PHASE1":730,"PHASE1":732,"PHASE2":734,"PHASE3":736,"PHASE4":738,"NA":740},{"trials":731,"activeCount":61},[],{"trials":733,"activeCount":61},[],{"trials":735,"activeCount":61},[],{"trials":737,"activeCount":61},[],{"trials":739,"activeCount":61},[],{"trials":741,"activeCount":61},[742],{"nctId":712,"briefTitle":713,"status":664,"phases":743,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":744,"interventions":745},[54],[720,721],[697,723,724,725,726,727],{"intervention":724,"totalTrials":95,"cells":747},{"EARLY_PHASE1":748,"PHASE1":750,"PHASE2":752,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":749,"activeCount":61},[],{"trials":751,"activeCount":61},[],{"trials":753,"activeCount":61},[],{"trials":755,"activeCount":61},[],{"trials":757,"activeCount":61},[],{"trials":759,"activeCount":61},[760],{"nctId":712,"briefTitle":713,"status":664,"phases":761,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":762,"interventions":763},[54],[720,721],[697,723,724,725,726,727],{"intervention":725,"totalTrials":95,"cells":765},{"EARLY_PHASE1":766,"PHASE1":768,"PHASE2":770,"PHASE3":772,"PHASE4":774,"NA":776},{"trials":767,"activeCount":61},[],{"trials":769,"activeCount":61},[],{"trials":771,"activeCount":61},[],{"trials":773,"activeCount":61},[],{"trials":775,"activeCount":61},[],{"trials":777,"activeCount":61},[778],{"nctId":712,"briefTitle":713,"status":664,"phases":779,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":780,"interventions":781},[54],[720,721],[697,723,724,725,726,727],{"intervention":726,"totalTrials":95,"cells":783},{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":794},{"trials":785,"activeCount":61},[],{"trials":787,"activeCount":61},[],{"trials":789,"activeCount":61},[],{"trials":791,"activeCount":61},[],{"trials":793,"activeCount":61},[],{"trials":795,"activeCount":61},[796],{"nctId":712,"briefTitle":713,"status":664,"phases":797,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":798,"interventions":799},[54],[720,721],[697,723,724,725,726,727],{"intervention":727,"totalTrials":95,"cells":801},{"EARLY_PHASE1":802,"PHASE1":804,"PHASE2":806,"PHASE3":808,"PHASE4":810,"NA":812},{"trials":803,"activeCount":61},[],{"trials":805,"activeCount":61},[],{"trials":807,"activeCount":61},[],{"trials":809,"activeCount":61},[],{"trials":811,"activeCount":61},[],{"trials":813,"activeCount":61},[814],{"nctId":712,"briefTitle":713,"status":664,"phases":815,"primaryCompletion":715,"completion":716,"start":717,"enrollment":718,"conditions":816,"interventions":817},[54],[720,721],[697,723,724,725,726,727],{"intervention":819,"totalTrials":95,"cells":820},"Propofol sedation by nurse anaesthestist",{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":827,"PHASE4":829,"NA":831},{"trials":822,"activeCount":61},[],{"trials":824,"activeCount":61},[],{"trials":826,"activeCount":61},[],{"trials":828,"activeCount":61},[],{"trials":830,"activeCount":61},[],{"trials":832,"activeCount":61},[833],{"nctId":834,"briefTitle":835,"status":71,"phases":836,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":840,"interventions":842},"NCT01505218","Propofol Patient-controlled Sedation for Endoscopic Retrograde Cholangiopancreatography",[54],"2012-05","2010-10",281,[841],"Endoscopic Retrograde Cholangiopancreatography",[819,843],"Patient-controlled propofol sedation",{"intervention":843,"totalTrials":95,"cells":845},{"EARLY_PHASE1":846,"PHASE1":848,"PHASE2":850,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":847,"activeCount":61},[],{"trials":849,"activeCount":61},[],{"trials":851,"activeCount":61},[],{"trials":853,"activeCount":61},[],{"trials":855,"activeCount":61},[],{"trials":857,"activeCount":61},[858],{"nctId":834,"briefTitle":835,"status":71,"phases":859,"primaryCompletion":837,"completion":837,"start":838,"enrollment":839,"conditions":860,"interventions":861},[54],[841],[819,843],{"intervention":863,"totalTrials":95,"cells":864},"Autologous platelets",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":866,"activeCount":61},[],{"trials":868,"activeCount":61},[],{"trials":870,"activeCount":61},[],{"trials":872,"activeCount":61},[],{"trials":874,"activeCount":61},[],{"trials":876,"activeCount":61},[877],{"nctId":878,"briefTitle":879,"status":71,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":241,"conditions":883,"interventions":887},"NCT00537784","Platelet Concentrate in Achilles Tendon Repair",[54],"2009-07","2007-09",[884,885,886],"Achilles Tendon Rupture","Soft Tissue Injury","Tendon Injury",[863,888],"no",{"intervention":888,"totalTrials":95,"cells":890},{"EARLY_PHASE1":891,"PHASE1":893,"PHASE2":895,"PHASE3":897,"PHASE4":899,"NA":901},{"trials":892,"activeCount":61},[],{"trials":894,"activeCount":61},[],{"trials":896,"activeCount":61},[],{"trials":898,"activeCount":61},[],{"trials":900,"activeCount":61},[],{"trials":902,"activeCount":61},[903],{"nctId":878,"briefTitle":879,"status":71,"phases":904,"primaryCompletion":881,"completion":881,"start":882,"enrollment":241,"conditions":905,"interventions":906},[54],[884,885,886],[863,888],{"intervention":908,"totalTrials":95,"cells":909},"Blueberries",{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":918,"NA":920},{"trials":911,"activeCount":61},[],{"trials":913,"activeCount":61},[],{"trials":915,"activeCount":61},[],{"trials":917,"activeCount":61},[],{"trials":919,"activeCount":61},[],{"trials":921,"activeCount":61},[922],{"nctId":923,"briefTitle":924,"status":71,"phases":925,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":934},"NCT01274078","Effects of Exercise With or Without Blueberries on Cardiovascular Risk Markers",[54],"2010-12","2011-03","2010-07",32,[931,580,932,933],"Risk Factors Cardiovascular Disease","Exercise","Sedentary Life",[908]]